Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism in the direct oral anticoagulants era: Findings from the TULIPE registry
Rezidiv- und Blutungsrisiko bei patient:innen mit krebsassoziierter venöser Thromboembolie in der DOAC-Ära: Ergebnisse aus dem TULIPE-Register
PLOS One · 29.07.2025 · 20 (7) · e0329025
DOI: 10.1371/journal.pone.0329025 ↗Auf einen Blick
Bei 2.281 Patient:innen mit tiefer Venenthrombose traten bei aktiver Krebserkrankung mehr Rezidive und schwere Blutungen auf als ohne Krebs. Das Risiko blieb auch nach Adjustierung erhöht.
Fragestellung
Wie unterscheiden sich Rezidiv- und Blutungsrisiko bei Krebs- und Nicht-Krebs-assoziierter venöser Thromboembolie in der DOAC-Ära?
Methode
Retrospektive Analyse von DVT-Patient:innen per Beinvenen-Ultraschall am Universitätskrankenhaus Tsukuba zwischen Januar 2015 und August 2020.
Ergebnisse
2.281 Patient:innen: 1.152 mit aktivem Krebs und 1.129 ohne Krebs. 5-Jahres-Rezidiv: 25 % vs. 10 %; adjustierte sHR 2,00 (95 %-KI 1,46–2,74). 5-Jahres-Major-bleeding: 30 % vs. 9,6 %; adjustierte sHR 2,69 (95 %-KI 1,90–3,81).
Schlussfolgerung der Autor:innen
In der DOAC-Ära hatten Patient:innen mit Krebs ähnlich wie in der Warfarin-Ära deutlich höhere Raten an VTE-Rezidiv und major bleeding als Patient:innen ohne Krebs.
Kernaussagen
- 5-Jahres-Rezidiv bei Krebs: 25 % vs. 10 % ohne Krebs
- Major bleeding: 30 % vs. 9,6 %
- Krebs blieb nach Adjustierung ein Risikofaktor für beides
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 29.07.2025. Verfasst von Yuki Ishizuka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Venous Thromboembolism, Neoplasms, Hemorrhage, Anticoagulants. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Center Research and Development Fund, MHLW Research for Promotion of Cancer Control Programs.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
The introduction of direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) treatment has led to their widespread adoption in clinical practice, potentially influencing management strategies and patient outcomes. However, real-world data on cancer-associated VTE in the DOAC era remain limited. This study aimed to evaluate the clinical characteristics and long-term outcomes of patients with cancer- and non-cancer-associated VTE in a real-world setting.
Methods
We retrospectively analyzed patients diagnosed with deep vein thrombosis (DVT) using lower-extremity venous ultrasound between January 2015 and August 2020 at the University of Tsukuba Hospital, a tertiary academic referral center in Japan.
Results
The cohort included 2,281 patients with DVT, comprising 1,152 with active cancer (cancer group) and 1,129 without cancer (non-cancer group). The cumulative 5-year incidence of recurrent VTE was significantly higher in the cancer group than in the non-cancer group (25% vs. 10%, P < 0.001). After adjusting for confounders and accounting for the competing risk of mortality, cancer remained a significant risk factor for recurrence (adjusted subdistribution hazard ratio [sHR]: 2.00; 95% confidence interval [CI]: 1.46–2.74). Similarly, the cumulative 5-year incidence of major bleeding was significantly higher in the cancer group (30% vs. 9.6%, P < 0.001). After adjustment, the risk of major bleeding remained significantly elevated in the cancer group compared to that in the non-cancer group (adjusted sHR: 2.69; 95% CI: 1.90–3.81). In the cancer group, discontinuation of bleeding-related anticoagulation therapy was associated with increased VTE recurrence (P < 0.001), whereas no such association was observed in the non-cancer group (P = 0.716).
Conclusions
In the DOAC era, similar to the warfarin era, patients with cancer exhibited significantly higher rates of VTE recurrence and major bleeding than those without cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
- Department of Cardiology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
- Department of Cardiology, National Cancer Center Hospital East, Kashiwa, Japan.
- Tsukuba Life Science Innovation Program (T-LSI), School of Integrative and Global Majors (SIGMA), University of Tsukuba, Tsukuba, Japan.
- Clinical Laboratory, Hidaka Hospital, Takasaki, Japan.
- Department of Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
ORCID-Profile: Kazuko Tajiri, Tomoko Machino-Ohtsuka, Tomoko Ishizu
Förderung
- National Cancer Center Research and Development Fund
- MHLW Research for Promotion of Cancer Control Programs
Zitieren
APA
Ishizuka, Y., Tajiri, K., Naito, H., Murata, M., Hattori, M., Machino-Ohtsuka, T., & Ishizu, T. (2025). Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism in the direct oral anticoagulants era: Findings from the TULIPE registry. PLOS One, 20(7), e0329025. https://doi.org/10.1371/journal.pone.0329025
Vancouver
Ishizuka Y, Tajiri K, Naito H, Murata M, Hattori M, Machino-Ohtsuka T, et al. Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism in the direct oral anticoagulants era: Findings from the TULIPE registry. PLOS One. 2025;20(7):e0329025. doi:10.1371/journal.pone.0329025
BibTeX
@article{Ishizuka2025,
author = {Ishizuka, Yuki and Tajiri, Kazuko and Naito, Hiroyuki and Murata, Momoko and Hattori, Masayuki and Machino-Ohtsuka, Tomoko and Ishizu, Tomoko},
title = {Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism in the direct oral anticoagulants era: Findings from the TULIPE registry},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {7},
pages = {e0329025},
doi = {10.1371/journal.pone.0329025}
}
EUVIMED